Medical Center Excelsior OOD

The trials here

What the 43 trials at this site are about, from their registry records.

Conditions

• Asthma12 trials
• Atopic dermatitis (eczema)8 trials
• Lupus (SLE)6 trials
• Psoriatic arthritis4 trials
• COPD3 trials
• Psoriasis3 trials
• Obesity2 trials
• Osteoarthritis2 trials
• Sjögren's disease2 trials
• Alopecia areata1 trial
• Ankylosing spondylitis1 trial
• Coronary artery disease1 trial
• and 4 more

Phase

• Phase 321 trials
• Phase 218 trials
• Phase 42 trials
• Phase 11 trial
• Phase 2/31 trial

Status

• Completed20 trials
• Active, not recruiting13 trials
• Not yet recruiting5 trials
• Recruiting5 trials

Lead sponsor

• AbbVie3 trials
• Chiesi Farmaceutici S.p.A.3 trials
• Sanofi3 trials
• Amgen2 trials
• Amgen Inc.2 trials
• and 26 more

Running trials

• Not yet recruiting

  A Trial of LAD603 in Patients with Systemic Lupus Erythematosus

  2026-527200-24-00· Phase 2· Almirall S.A.· Source

• Not yet recruiting

  A study to Evaluate the Efficacy and Safety of ENV-294 in Adult Participants with Moderate-to-Severe Atopic Dermatitis

  2026-526184-38-00· Phase 2· Enveda Therapeutics Inc.· Source

• Recruiting

  A Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma

  NCT07532265· Phase 2· Kinaset Therapeutics Inc· Source

• Recruiting

  A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

  NCT07690371· Phase 3· Nektar Therapeutics· Source

• Recruiting

  BETRI-Prospective: Asthma Control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 μg]) vs Single Inhaler ICS/LABA (200/6 pMDI [BDP/FF - 200/6 μg])

  NCT07666490· Phase 4· Chiesi Farmaceutici S.p.A.· Source

• Recruiting

  AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

  NCT07509307· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

  NCT07481630· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  A study to investigate the efficacy and safety of TRIV-509 compared with placebo in adults with moderate to severe atopic dermatitis

  2025-522113-35-00· Phase 2· Triveni Bio Inc.· Source

• Recruiting

  A Study of LAD603 in Adults With Alopecia Areata

  NCT07311564· Phase 2· Almirall, S.A.· Source

• Recruiting

  A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)

  NCT07276724· Phase 3· Generate Biomedicines· Source

• Recruiting

  A first-in-human, dose finding study to evaluate the safety, tolerability and pharmacokinetics of EGL-003 in healthy volunteers followed by adults with autoimmune disease.

  2025-521658-40-00· Phase 1· Egle Therapeutics· Source

• Active, not recruiting

  Trial of Sibeprenlimab in the Treatment of Sjögren’s Disease

  2024-516295-14-00· Phase 2· Otsuka Pharmaceutical Development & Commercialization Inc.· Source

• Recruiting

  Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma

  NCT07120503· Phase 2· Windward Bio· Source

• Active, not recruiting

  A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)

  NCT06966479· Phase 2· Upstream Bio Inc.· Source

• Active, not recruiting

  A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis

  NCT06136741· Phase 2· Nektar Therapeutics· Source

• Active, not recruiting

  Phase 2 Placebo-controlled Study to Assess the Safety, Efficacy, and PK of ESK-001 in SLE

  2022-502105-15-00· Phase 2· Alumis Inc.· Source

• Active, not recruiting

  A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations

  NCT06052267· Phase 3· Teva Branded Pharmaceutical Products R&D LLC· Source

• Active, not recruiting

  Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

  NCT05843643· Phase 3· AbbVie· Source

• Recruiting

  Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE (POETYK SLE-1)

  2022-500699-76-00· Phase 3· Bristol-Myers Squibb Services Unlimited Company· Source

• Active, not recruiting

  Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma

  NCT05097287· Phase 4· Sanofi· Source

• Active, not recruiting

  A Study of Guselkumab in Participants With Active Psoriatic Arthritis

  NCT04882098· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus

  NCT04877691· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy

  NCT03675308· Phase 3· AbbVie· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Asthma4 recruiting
• Atopic dermatitis (eczema)3 recruiting
• Alopecia areata1 recruiting
• Lupus (SLE)1 recruiting
• Obesity1 recruiting
• Osteoarthritis1 recruiting

Closed trials

• Terminated

  Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa

  NCT06555328· Phase 2· InflaRx GmbH· Source

• Completed

  A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjögren’s Syndrome

  NCT06312020· Phase 2· Horizon Therapeutics Ireland Designated Activity Company· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis

  NCT06624228· Phase 3· UCB Biopharma SRL· Source

• Completed

  A Phase 2, Double-blind, Placebo-controlled, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma

  NCT06376045· Phase 2· Amgen Inc.· Source

• Completed

  A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)

  NCT06196879· Phase 2· Upstream Bio Inc.· Source

• Completed

  A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD

  NCT06208306· Phase 3· Sanofi· Source

• Completed

  A Phase 2 study to evaluate the efficacy and safety of RPT193 in adults with moderate-to-severe T2-high asthma who are partially controlled on inhaled corticosteroid and long-acting beta 2 agonist therapy

  2022-502854-16-00· Phase 2· Rapt Therapeutics Inc.· Source

• Completed

  Efficacy and safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund maintenance therapy

  2022-502208-64-00· Phase 2· Chiesi Farmaceutici S.p.A.· Source

• Completed

  A Phase 3, Double-blind Maintenance Study Assessing Rocatinlimab in Moderate-to-severe AD (ROCKET-ASCEND)

  NCT05882877· Phase 3· Amgen Inc.· Source

• Completed

  A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus

  NCT05856448· Phase 2· Lakefront Biotherapeutics NV· Source

• Completed

  A study to test if izokibep improves psoriatic arthritis symptoms and to see how safe izokibep is

  2022-501362-22-00· Phase 2/3· Acelyrin Inc.· Source

• Completed

  Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients

  NCT05586971· Phase 3· LG Chem· Source

• Completed

  A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)

  NCT05724199· Phase 3· Amgen· Source

• Completed

  A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis

  NCT05437263· Phase 3· Priovant Therapeutics, Inc.· Source

• Completed

  A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD

  NCT04320342· Phase 3· Chiesi Farmaceutici S.p.A.· Source

• Completed

  Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma

  NCT05251259· Phase 2· AstraZeneca· Source

• Completed

  Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)

  NCT04701983· Phase 3· Sanofi· Source

• Completed

  Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

  NCT03989206· Phase 3· Galderma R&D· Source

• Completed

  A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis

  NCT04169373· Phase 3· AbbVie· Source

• Completed

  Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

  NCT03872401· Phase 3· Amgen· Source